# Valneva

Type: Company (VALN)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/valneva
Canonical HTML page: https://gethealthbrief.com/entity/valneva

## Timeline

- **2025**: Regulatory Submission — Anticipated filing for FDA and EMA approval based on final trial data.
- **2024-03**: Efficacy Milestone — Trial results indicate efficacy exceeding the 70% threshold.
- **2022-08**: Phase 3 Launch — The VALOR trial begins enrolling thousands of participants in endemic areas.
- **2020-04**: Partnership Formed — Pfizer and Valneva enter a collaboration agreement to develop VLA15.

## Recent coverage (2 stories)

### 476,000 Lyme Cases Annually: Will Hunters Embrace a New Vaccine?
2026-08-07 07:55:57 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

As Pfizer and Valneva seek approval for a new Lyme disease vaccine, healthcare providers confront the challenge of convincing high-risk, rural hunters—who skew vaccine-hesitant—to embrace immunization amid rising tick-borne illness.
Full story: https://gethealthbrief.com/story/hunters-lyme-vaccine-health-2026

### Pfizer Reports Over 70% Efficacy for Landmark Lyme Disease Vaccine Trial
2026-03-25 02:02:21 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

Pfizer and Valneva have announced that their Lyme disease vaccine candidate, VLA15, demonstrated more than 70% efficacy in late-stage clinical trials. This breakthrough marks the first successful human vaccine development for the tick-borne illness in over two decades, addressing a critical gap in public health.
Full story: https://gethealthbrief.com/story/pfizer-lyme-vaccine-efficacy-results

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.